Ken Griffin Pro Qr Therapeutics N.V. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 379,263 shares of PRQR stock, worth $724,392. This represents 0.0% of its overall portfolio holdings.
Number of Shares
379,263
Previous 3,600
10435.08%
Holding current value
$724,392
Previous $4,000
19225.0%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding PRQR
# of Institutions
65Shares Held
41.2MCall Options Held
26KPut Options Held
0-
Adage Capital Partners Gp, L.L.C. Boston, MA6.6MShares$12.6 Million0.02% of portfolio
-
Privium Fund Management B.V.5MShares$9.55 Million2.17% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.5MShares$6.68 Million1.2% of portfolio
-
Morgan Stanley New York, NY3.08MShares$5.89 Million0.0% of portfolio
-
Sio Capital Management, LLC New York, NY2.08MShares$3.96 Million2.02% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $136M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...